Last $9.05 USD
Change Today -0.51 / -5.33%
Volume 229.8K
BIND On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

bind therapeutics inc (BIND) Snapshot

Open
$9.56
Previous Close
$9.56
Day High
$9.74
Day Low
$8.55
52 Week High
10/15/13 - $15.89
52 Week Low
06/2/14 - $8.00
Market Cap
149.7M
Average Volume 10 Days
99.5K
EPS TTM
$-4.22
Shares Outstanding
16.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIND THERAPEUTICS INC (BIND)

Related News

No related news articles were found.

bind therapeutics inc (BIND) Related Businessweek News

No Related Businessweek News Found

bind therapeutics inc (BIND) Details

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. The company’s lead Accurin drug candidate includes BIND-014, a prostate-specific membrane antigen targeted Accurin that contains docetaxel and is in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. It has collaboration agreements to develop Accurins based on therapeutic payloads from their product pipelines with Amgen, Inc.; Pfizer Inc.; and AstraZeneca AB. The company was formerly known as BIND Biosciences, Inc. and changed its name to BIND Therapeutics, Inc. in April 2013. BIND Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

59 Employees
Last Reported Date: 03/25/14
Founded in 2006

bind therapeutics inc (BIND) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $395.0K
Chief Technology Officer
Total Annual Compensation: $301.3K
Advisor
Total Annual Compensation: $247.9K
Compensation as of Fiscal Year 2013.

bind therapeutics inc (BIND) Key Developments

BIND Therapeutics, Inc. Announces Board Appointments

BIND Therapeutics, Inc. announced the appointments of Eric K. Rowinsky, M.D. and Amy W. Schulman to the company's board of directors. Eric K. Rowinsky, M.D., currently serves as Head of Research and Chief Medical Officer at Stemline Therapeutics and as a board member of Biogen Idec Inc. and was formerly Executive Vice President of Clinical Development and Regulatory at ImClone Systems. Amy W. Schulman is the Chief Executive Officer of Arsia Therapeutics and a Venture Partner at Polaris Partners. She is the former Executive Vice President and General Counsel of Pfizer Inc. and served as the Business Unit Lead for Pfizer's Consumer Healthcare business, after serving as President of the Nutrition Business.

BIND Therapeutics, Inc. Announces Presentation of Phase 2 Clinical Data on Bind-014 at 26th EORTC-NCI-AACR Symposium

BIND Therapeutics, Inc. announced that a poster presentation including Phase 2 clinical data on its lead drug candidate, BIND-014, in patients with non-small cell lung cancer (NSCLC) will be presented at the upcoming 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. BIND-014 is a PSMA targeted polymeric nanoparticle containing the cytotoxic agent docetaxel. In preclinical cancer models, BIND-014 was shown to increase accumulation of docetaxel in tumors which translated to marked improvements in antitumor activity. In a Phase 1 study, BIND-014 was well tolerated and showed initial indications of anti-tumor activity. BIND-014 is currently in two Phase 2 trials for the treatment of non-small cell lung cancer and metastatic castrate resistant prostate cancer.

BIND Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014

BIND Therapeutics, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $2,459,000, loss from operations of $8,216,000, net loss attributable to common stockholders of $8,444,000 or $0.51 per basic and diluted share compared to the revenue of $2,777,000, loss from operations of $5,632,000, net loss attributable to common stockholders of $7,331,000 or $3.32 per basic and diluted share for the same quarter a year ago. For the six months period, the company reported revenue of $4,024,000, loss from operations of $16,735,000, net loss attributable to common stockholders of $16,766,000 or $1.02 per basic and diluted share compared to the revenue of $4,265,000, loss from operations of $11,768,000, net loss attributable to common stockholders of $14,957,000 or $6.83 per basic and diluted share for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIND:US $9.05 USD -0.51

BIND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIND.
View Industry Companies
 

Industry Analysis

BIND

Industry Average

Valuation BIND Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.0x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIND THERAPEUTICS INC, please visit bindtherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.